Depakote
(Valproic Acid)ApprovedSmall molecule
AbbVieValproic acid is used to treat seizures and epilepsy, and is also used to prevent migraines and treat mood disorders like bipolar disorder.[2] Depakote is currently approved and in use across 69 indications[4].[1]
Depakote is one of 1476 small molecule programs targeting Glioma. It is currently in Approved.
69
Indications
104
Total Trials
9
Active Trials
1,475
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 69 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Depakote
AbbVieApproved
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Avastin
RochePreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Perflutren Lipid Microcpheres
TThomas Jefferson University
Preclinical
Escitalopram Oxalate
TTorrent Pharmaceuticals Limited
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bipolar Disorder5 trials
Bipolar Disorder in Late Life
Completed·—··NCT00787930·19 enrolled
Status Epilepticus3 trials
Radiation Therapy3 trials
Migraine3 trials
Tics3 trials
The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000629·6 enrolled
71 more indications
Chronic Lymphocytic Leukemia3 trials
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
Unknown status·—·Phase 2·NCT01016990·52 enrolled
Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)
Unknown status·—·N/A·NCT00810680·10 enrolled
Epilepsy3 trials
The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children
Unknown status·—·Phase 4·NCT05697614·100 enrolled
HIV2 trials
Head and Neck Squamous Cell Carcinoma2 trials
Retinitis Pigmentosa2 trials
Azacytidine2 trials
OIC2 trials
Valproic Acid in Treating Cyanotic Breath Holding Spells
Completed·—·Phase 1·NCT04482764·150 enrolled
Safety and Efficiency Study of Valproic Acid In HAM/TSP
Terminated·—·N/A·NCT00519181·19 enrolled
Spinal Muscular Atrophy2 trials
Nasopharyngeal Carcinoma2 trials
Ovarian Cancer2 trials
Myelodysplastic Syndrome2 trials
Thyroid Cancer2 trials
Acute Kidney Injury2 trials
ART1 trial
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)
Completed·—·Phase 1·NCT01951560·59 enrolled
Myelodysplastic Syndromes1 trial
Metastatic Colorectal Cancer1 trial
Breast Cancer1 trial
Glioma1 trial
Recurrent or Refractory Solid Tumors1 trial
Treatment1 trial
Adjuvant1 trial
Adjuvant Valproate for High Grade Sarcomas
Terminated·—·Phase 1·NCT01010958·7 enrolled
Amputation1 trial
Valproic Acid for the Prevention of Post-Amputation Pain
Completed·—·Phase 2·NCT01928849·128 enrolled
Bevacizumab1 trial
Tropical Spastic Paraparesis1 trial
Bladder Cancer1 trial
Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
Completed·SState University of New York - Upstate Medical University·Phase 1·NCT01738815·43 enrolled
Soft Tissue Sarcoma1 trial
Metastatic Prostate Cancer1 trial
Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00670046·15 enrolled
Squamous Cell Carcinoma1 trial
Fear of Spiders1 trial
Pancreatic Adenocarcinoma1 trial
Infantile Spasms1 trial
Uveal Melanoma1 trial
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02068586·210 enrolled
Solid Tumor Malignancies1 trial
Lymphoproliferative Syndrome1 trial
Adult T-Cell Leukemia/lymphoma1 trial
Childhood Absence Epilepsy1 trial
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
Completed·—·Phase 3·NCT00088452·453 enrolled
Body Weight1 trial
Patients With Solid Tumors1 trial
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Recruiting·—·Phase 1·NCT02446431·20 enrolled
Lymphoma1 trial
Non-Small Cell Lung Cancer1 trial
Hematological Malignancies1 trial
Progressive Supranuclear Palsy1 trial
Diffuse Intrinsic Pontine Glioma1 trial
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Completed·—·Phase 2·NCT00879437·38 enrolled
Trauma1 trial
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)
Terminated·—·Phase 1·NCT02872428·1 enrolled
Advanced Solid Tumor1 trial
Bipolar I Disorder1 trial
Colorectal Cancer1 trial
Catheter1 trial
Prolonged1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
DEPAKENE
NDA NDA018081
Jan 1, 1982
DEPAKENE
NDA NDA018082
Jul 29, 2008
STAVZOR
NDA NDA022152
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Depakote drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Valproic Acid. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]